Abstract
THE advances in biochemistry of the past decade have revealed that the defects in carbohydrate metabolism in diabetes involve several distinct areas in hepatic metabolism, together with a defect in transport of glucose into peripheral muscle.1 This has prepared for the possibility of correction of one or more of these, separately or together, by pharmacologic agents simpler in structure than insulin and capable of absorption by the gastrointestinal tract. The recently introduced hypoglycemic agents for oral administration fit this description. They are of two classes, the sulfonylureas (tolbutamide† and chlorpropamide‡)1 , 2 and the diguanides (phenethyldiguanide§).1 , 3 The sulfonylureas stimulate the . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
